<DOC>
	<DOC>NCT00903253</DOC>
	<brief_summary>The objective of this study is to evaluate the single-dose plasma pharmacokinetics of LNK-754 as well as safety and tolerability in normal healthy male and female elderly volunteers</brief_summary>
	<brief_title>A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers</brief_title>
	<detailed_description />
	<criteria>Males and Females aged 60 to 75 years Good general health as determined by medical history and physical examination Body Mass Index of 1832, inclusive Estimate of creatinine clearance by CockcroftGault that is normal for age and sex (greater than or equal to 60mL/min) Normal hemoccult test at screening and baseline Voluntarily consent to participate in the study Willing to adhere to the protocol requirements Subjects with clinically significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurological, sleep disorders by DSMIV criteria, endocrine, hematological, or metabolic disease as determined by medical history and physical examination Subjects who have been diagnosed with or meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSMIV_TR) criteria for any significant psychiatric or psychoactive substance use disorder within the past year Subjects with positive urine drug screen or compounds associated with abuse in the absence of medical justification for their presence QTcB greater than 450 msec (males), or greater than 470 (females), based on the average interval of triplicate ECGs obtained after five minutes rest in a supine position using hte ECG algorithm Clinically significant abnormal screening results or laboratory tests Pregnant or nursing or planning a pregnancy, or planning on fathering a child</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>